anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a method of delivering drugs having anti-proliferative activity in the cardiovascular system to a tissue or circulation using a drug-coated medical device. The drug-coated medical device is brought into contact with the target tissue or circulation and the drugs are quickly released into the area surrounding the device in a short time after the contact step. The release times may include 30 seconds, 1 minute or 3 minutes. Once the therapeutic drugs are released, they are quickly and effectively absorbed by the surrounding cells or circulation. The therapeutic drug may have sustained anti-proliferative activity and thus a prolonged effect. The therapeutic drug, which inhibits proliferative activity in the cardiovascular system, may be preferably encapsulated in a controlled release carrier. In a preferred embodiment, the controlled release carrier may be a liposome, drug aggregate, microparticle or nanoparticle and the therapeutic agent may be a bisphosphonate.
Participants will not receive any drug. They will be asked to return 1-6 weeks after the screening visit for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, rectal swabs, urine sample, and rectal biopsy via rigid sigmoidoscopy.
Subjects will be diagnosed via two methods: 1. Target Enriched Multiplex PCR (TEM- PCR) and 2. Standard microbial culture.
Currently, no consensus has been established on the most effective antithrombotic therapy to prevent thromboembolic and bleeding events in patients undergoing percutaneous left atrial appendage closure (LAAC) with preprocedural thromboembolic or bleeding events under oral anticoagulation (OAC) therapy. We retrospectively investigated the incidence of device-related thrombosis (DRT), thromboembolic events, and bleeding events in patients who underwent LAAC from September 2019 to October 2022. After categorizing patients into three groups based on preprocedural thromboembolic or bleeding events under OAC therapy, we compared the incidence of DRT and prognosis according to the postprocedural antithrombotic therapy. In patients who received the conventional antithrombotic therapy (OAC with and without single antiplatelet therapy for 45 days after LAAC and dual-antiplatelet therapy from 45 days to 6 months followed by single antiplatelet therapy), preprocedural thromboembolic events despite OAC were independently associated with DRT or postprocedural thromboembolic events at the 3 year follow-up (hazard ratio [HR] 4.55; 95% confidence interval [CI] 1.32-15.6; P = 0.016), whereas preprocedural bleeding events were independently associated with postprocedural bleeding events (HR 8.01, 95% CI 1.45-58.3; P = 0.036). Continuation of OAC for 12 months among patients who developed preprocedural thromboembolic events during OAC significantly decreased the incidence of DRT or postoperative thromboembolic events (P = 0.002) with no increase in the bleeding events (P = 0.522). Preprocedural thromboembolic and bleeding events can predict adverse events after LAAC with the conventional antiplatelet-based antithrombotic therapy. Patients who develop thromboembolic events under continuous OAC may benefit from continuous OAC for 1 year after LAAC.
The invention relates to a traditional Chinese medicine preparation and especially relates to a traditional Chinese medicine for treating laryngeal polypus and a preparation method thereof. The traditional Chinese medicine for treating the laryngeal polypus is mainly composed of following raw materials including, by weight, 250g of fructus mume, 250g of white muscardine silkworms, 100g of safflower, 100g of zedoary, 100g of terminalia chebula, 100g of lasiosphaera and 100g of anemone chinensis. The traditional Chinese medicine is safe, convenient and easy to use, is free of pain and toxicity, is free of allergy and is quite good in curative effects. The raw materials are rich in sources and low in costs. Production equipment is low in cost. The traditional Chinese medicine is wide in available patient scope, is quite good in the curative effect on patients whom are definitely diagnosed but do not want operation, can quickly control and alleviate the laryngeal polypus after clinical medication and has a good curative effect on the patients whom are suffered from relapse after the operation.
The walls of microcapsules comprised of at least one gelable hydrophilic colloid which contains amino groups and peptide linkages and produced by a coacervation process (see Group VI) are rendered opaque and their impermeability to fluids increased by successive treatment with (a) at least one watersoluble and ionizable ferric salt and, (b) an aqueous solution of one or more of tannic acid, gallic acid and di-gallic acid.  Specified colloids of the above type are gelatin, fibrinogen, polylysine and polyrnithine.  Specifications 751,600, 911,483, 929,401, 929,402, 929,403, 929,408 and 929,409 are referred to.ALSO:Membranes comprising at least one gelable hydrophilic colloid which contains amino groups and peptide linkages (e.g. proteins and polyamines) and produced by coacervation techniques are treated successively with: (1) at least one water-soluble and ionizable ferric salt and (2) an aqueous solution of one or more of tannic acid, gallic acid and digallic acid.  The membranes may encapsulate solids, oils, oil-in-hydrophilic liquid and hydrophilic liquid-in-oil emulsions which may contain "active" ingredients which render the preparations of use as fertilizers, plant growth hormone preparations, bactericides, pesticides, vitamin preparations, pharmaceuticals and food-additives.  In particular, the treatment renders the membranes opaque and therefore increases the stability of encapsulated preparations comprising photosensitive materials, e.g. reserpine, hyoscyamine, potassium iodide, silver salts and phenyl mercuric acetate. Specified colloids are gelatine, fibrinogen, polylysine and polyornithine.  The coacervate must be gelled (e.g. by cooling) prior to the treatment with the ferric salt and may be present in the "spent" coacervating medium during the first or both steps of the treatment which preferably takes place at a pH of below 7. Specific examples refer to the treatment of: (a) aqueous potassium iodide-in-corn oil emulsion encapsulated in gelatine; (b) an ethanolic dispersion of silverbromide-in-silicone oil emulsion in gelatine; (c) aqueous epinephrine bitartrate-in-mineral oil emulsion in a complex coacervate of gelatine and styrene-maleic anhydride copolymer; (d) glyceryl monostearate coated yellow mercuric oxide in gelatine. Specifications 751,600, 911,483, 929,401, 929,402, 929,403, 929,408 and 929,409 are referred to.
Diabetes mellitus is a prevalent cause of mortality worldwide and can lead to several secondary issues, including DWs, which are caused by hyperglycemia, diabetic neuropathy, anemia, and ischemia. Roughly 15% of diabetic patient's experience complications related to DWs, with 25% at risk of lower limb amputations. A conventional management protocol is currently used for treating diabetic foot syndrome, which involves therapy using various substances, such as bFGF, pDGF, VEGF, EGF, IGF-I, TGF-β, skin substitutes, cytokine stimulators, cytokine inhibitors, MMPs inhibitors, gene and stem cell therapies, ECM, and angiogenesis stimulators. The protocol also includes wound cleaning, laser therapy, antibiotics, skin substitutes, HOTC therapy, and removing dead tissue. It has been observed that treatment with numerous plants and their active constituents, including Globularia Arabica, Rhus coriaria L., Neolamarckia cadamba, Olea europaea, Salvia kronenburgii, Moringa oleifera, Syzygium aromaticum, Combretum molle, and Myrtus communis, has been found to promote wound healing, reduce inflammation, stimulate angiogenesis, and cytokines production, increase growth factors production, promote keratinocyte production, and encourage fibroblast proliferation. These therapies may also reduce the need for amputations. However, there is still limited information on how to prevent and manage DWs, and further research is needed to fully understand the role of alternative treatments in managing complications of DWs. The conventional management protocol for treating diabetic foot syndrome can be expensive and may cause adverse side effects. Alternative therapies, such as medicinal plants and green synthesis of nano-formulations, may provide efficient and affordable treatments for DWs.
The invention provides a beta carboline-ruthenium complex, a preparation method and application thereof, and belongs to the technical field of organic matter synthesis. The invention takes L-tryptophan as an initial raw material, and the derivative is connected with metal ruthenium to further synthesize two metal ruthenium complexes Ru1 and Ru2 containing beta carboline. The two beta carboline-ruthenium complexes provided by the invention can trigger the generation of intracellular active oxygen and reduce the content of intracellular GSH, and can be used as a ruthenium photosensitizer to induce liver cancer cells to generate pyrosis. Under light irradiation, the ruthenium complex induces the cells to produce toxic active oxygen, resulting in cell membrane disruption, lysosome damage and mitochondrial dysfunction. And destroy the antioxidant system activated by tumor cells, and enhance the sensitivity of the tumor cells to ROS. Wherein, ru2 illumination-induced programmed cell apoptosis can still enhance the treatment effect in vivo and effectively inhibit the growth of tumor tissues.
Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
Adult Rheumatoid Arthritis: Recommended Starting Dosage Schedules

1\. Single oral doses of 7.5 mg once weekly.

2\. Divided oral dosages of 2.5 mg at 12 hour intervals for 3 doses given as a course once weekly.

Polyarticular-Course Juvenile Rheumatoid Arthritis: The recommended starting dose is 10 mg/m2 given once weekly. 

For either adult RA or polyarticular-course JRA dosages may be adjusted gradually to achieve an optimal response. Limited experience shows a significant increase in the incidence and severity of serious toxic reactions, especially bone marrow suppression, at doses greater than 20 mg/wk in adults. Although there is experience with doses up to 30 mg/m2/wk in children, there are too few published data to assess how doses over 20 mg/m2/wk might affect the risk of serious toxicity in children. Experience does suggest, however, that children receiving 20 to 30 mg/m2/wk (0.65 to 1.0 mg/kg/wk) may have better absorption and fewer gastrointestinal side effects if methotrexate is administered either intramuscularly or subcutaneously. 

Therapeutic response usually begins within 3 to 6 weeks and the patient may continue to improve for another 12 weeks or more.

The optimal duration of therapy is unknown. Limited data available from long-term studies in adults indicate that the initial clinical improvement is maintained for at least two years with continued therapy. When methotrexate is discontinued, the arthritis usually worsens within 3 to 6 weeks.

The patient should be fully informed of the risks involved and should be under constant supervision of the physician. (See Information for Patients under PRECAUTIONS.) Assessment of hematologic, hepatic, renal, and pulmonary function should be made by history, physical examination, and laboratory tests before beginning, periodically during, and before reinstituting methotrexate therapy. (See PRECAUTIONS.) Appropriate steps should be taken to avoid conception during methotrexate therapy. (See PRECAUTIONS and CONTRAINDICATIONS.)

All schedules should be continually tailored to the individual patient. An initial test dose may be given prior to the regular dosing schedule to detect any extreme sensitivity to adverse effects. (See ADVERSE REACTIONS.) Maximal myelosuppression usually occurs in seven to ten days.

Psoriasis: Recommended Starting Dose Schedules

1\. Weekly single oral, IM or IV dose schedule: 10 to 25 mg per week until adequate response is achieved.

2\. Divided oral dose schedule: 2.5 mg at 12-hour intervals for three doses.

Dosages in each schedule may be gradually adjusted to achieve optimal clinical response; 30 mg/week should not ordinarily be exceeded.

Once optimal clinical response has been achieved, each dosage schedule should be reduced to the lowest possible amount of drug and to the longest possible rest period. The use of methotrexate may permit the return to conventional topical therapy, which should be encouraged.
Rationale: There is growing evidence that an elevated homocysteine level is a risk factor for fracture incidence. The most common cause of homocysteine elevation is poor vitamin B12 and folate status. It is hypothesized that supplementation with 500 µg vitamin B12 and 400 µg folic acid will reduce fracture incidence in elderly people Main objective: to determine the efficacy of oral supplementation with vitamin B12 and folic acid in the prevention of fractures Study design: The trial is a randomized double-blind placebo-controlled trial, with two arms in parallel (placebo versus supplement). The intervention comprises a period of two years, and will be targeted to 3000 elderly subjects with elevated homocysteine levels. The study will be performed in institutions or residences for older persons around Wageningen, Rotterdam and Amsterdam.

Study population: 3000 elderly subjects (70 years and older) with elevated homocysteine levels Intervention (if applicable): One group receives daily a tablet with 500 µg vitamin B12 and 400 ug folic acid and the other group receives daily a placebo tablet. In both tablets 15 µg (600 IU) of vitamin D is included as well.

Main study parameters/endpoints: Fracture incidence is the primary outcome measure Time to fracture will be calculated. It is expected that in the intervention group 34% less fractures will occur than in the placebo group.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: First, participants need to be recruited. This will be done via information letters. Those who are interested have to complete a small questionnaire and then they will receive an information brochure. Upon continued interest in the intervention study, participants will be invited for a blood sampling. This blood sampling will take place (nearby or) at the location where the participants live. Immediately after the blood sampling a run-in period will start. Blood will be checked on homocysteine levels. Only participants with elevated levels of homocysteine will be included in the study. Two to four weeks after the run-in period the intervention study will be implemented. At the start of this intervention study several measurements will be performed and several questionnaires will be completed together with the participant at home. During the whole study participants need to take daily one tablet and they have to complete calenders to monitor fracture incidence. At the end of the study, blood sampling will be performed and several measurements and questionnaires will be repeated again at home.
PURPOSE OF REVIEW: Subclinical leaflet thrombosis (SLT) is often an incidental finding characterized by a thin layer of thrombus involving one, two or three leaflets, with typical appearance on multi-detector computed tomography (MDCT) of hypo-attenuating defect at the aortic side of the leaflet, also called hypo-attenuating leaflet thickening (HALT). SLT may occur following both transcatheter aortic replacement (TAVR) or biological surgical aortic valve replacement (SAVR). The aim of this review is to present an overview of the current state of knowledge on the incidence, diagnosis, clinical impact, and management of SLT following TAVR or SAVR.
RECENT FINDINGS: SLT occurs in 10-20% of patients following TAVR and is somewhat more frequent than following SAVR (5-15%). SLT may regress spontaneously without treatment in about 50% of the cases but may also progress to clinically significant valve thrombosis in some cases. Oral anticoagulation with vitamin K antagonist is reasonable if SLT is detected by echocardiography and/or MDCT during follow-up and is generally efficient to reverse SLT. SLT is associated with mild increase in the risk of stroke but has no impact on survival. SLT has been linked with accelerated structural valve deterioration and may thus impact valve durability and long-term outcomes.
SUMMARY: SLT is often an incidental finding on echocardiography or MDCT that occurs in 10-20% of patients following TAVR or 5-15% following biological SAVR and is associated with a mild increase in the risk of thrombo-embolic event with no significant impact on mortality but may be associated with reduced valve durability.
Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens that result in periods of profound neutropenia leaving patients susceptible to severe infectious complications. There are little clinical data to inform whether management of neutropenia post AML chemotherapy should occur in an outpatient or inpatient setting. Further, no studies have been conducted that assess the impact of neutropenia management strategy on the quality of life of pediatric patients with AML. Given that infectious complications are the leading cause of treatment related mortality among AML patients, it is important to identify the neutropenia management strategy that will lead to the best clinician- and patient- identified outcomes in order to improve the care of these patients.

This is a qualitative interview study where interviews of patients and/or caregivers will be performed. Participants will be patients less than 19 years of age at diagnosis (and their caregivers) receiving or having received chemotherapy for AML from eleven participating pediatric hospitals across the United States. Participants (children and caregivers) will be interviewed in an effort to develop a survey that captures patient- and caregiver- identified outcomes related to neutropenia management.
The present invention relates to a health care food prepared from pectin and propolis for protecting the gastrointestinal mucous membrane, which belongs to the technical field of a health care food. The present invention is prepared from the raw materials of the weight ratio: 10 to 40 parts of propolis and 10 to 50 parts of pectin. The present invention is taken by combining pectin and propolis. Because the limiting viscosity number of pectin in artificial gastric juice is 126, the control degree of gastrointestinal ulcer is more than 93%, the control degree of duodenal ulcer is 86.3%, and the effective rate of chronic gastritis lesion area is 96.3%. No LD50 is detected out, and thus, the present invention has high safety. Propolis can form a thin membrane which can not be penetrated by gastric acid on the gastrointestinal mucous membrane. The thin membrane acting on ulcer not only has disinfecting action, but also can protect and promote damaged tissues to reproduce and promote ulcer parts to heal. After the present invention is taken by a patient, the symptoms of gastritis, enteritis, gastric and duodenal ulcer, stomach pain, etc. gradually disappear, and the present invention has no side effect.
Patients admitted in ICU and planned to be intubated. Non-invasive sensor capable of measuring ORI (RAD - 97 pulse co-oximeter; Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.
INTRODUCTION: Interdigital neuroma (IN) is a benign enlargement of tissue surrounding the common plantar digital nerve. Although the standard surgical treatment of IN remains debated, recent attention has been given to less-invasive surgical decompression by intermetatarsal ligament (IML) release with neurolysis. This study aimed to compare the outcomes of IML release with neurolysis with standard interdigital neurectomy.
METHODS: A retrospective chart review was conducted on 350 consecutive patients who underwent surgical treatment of IN. Patients who satisfied our inclusion and exclusion criteria were categorized into two groups based on the surgical treatment received: IML release with neurolysis or interdigital neurectomy. Outcomes assessed included recurrence of symptoms, rate of revision surgery, and postoperative wound infection.
RESULTS: Of the total sample, 40 patients (31.5%) reported recurrence of symptoms within a 12-month follow-up period. Patients who underwent IML release with neurolysis had a markedly higher recurrence rate (47.50%) than those who underwent interdigital neurectomy (24.14%). The rate of postoperative wound infection was similar between the two groups. Binary logistic regression revealed that only the surgical technique was associated with the recurrence of symptoms. Despite the higher rate of symptom recurrence in the IML release with neurolysis patient group, the rate of revision surgery in those with symptom recurrence was similar between both groups.
DISCUSSION: IML release with neurolysis seems to have a higher risk of symptom recurrence than interdigital neurectomy. No patient-specific factors were identified as being associated with symptom recurrence. However, patients who did experience symptom recurrence in either surgical group had similar rates of revision surgery, which may be due to mild recurrent symptom severity in the IML release group that does not warrant revision surgery in these patients. Future studies should consider objective symptom recurrence severity and patient satisfaction.
LEVEL OF EVIDENCE: Level III.
The investigators will conduct a crossover design clinical trial to compare the effect of room air breathing (21% inspired oxygen) with pure oxygen breathing (100% inspired oxygen) on brain blood flow and cortical electrical activity. The study involves a one-time data collection taking place at University Hospitals Cleveland Medical Center on the Case Western Reserve University campus in Cleveland, Ohio. The investigators will perform neuroimaging (MRI) with electroencephalographic (EEG) cortical network mapping and cognitive assessments in all participants during room air breathing and again while breathing 100% pure oxygen. Oxygen will be delivered through a non-rebreather mask. Arterial blood partial pressure of oxygen (PaO2) will be measured twice, from arterial blood samples drawn during breathing room air prior to the MRI scan and again after 30 minutes of breathing 100% oxygen immediately following neuroimaging. Thus, the investigators will be able to determine if breathing pure oxygen may temporarily change brain blood flow and breathing, leading to changes in cognitive status such as euphoria or slowed reflexes. Information gained in this study may have direct operational relevance by helping us to understand one potential cause of "Unexplained Physiologic Events" that are reported in some aircraft pilots when flying at high altitude. Information gained could lead to development of new gas mixtures for use by personnel working in low oxygen high altitude environments.